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suppression after non-ablative conditioning for haploidentical
(3/6 and 4/6 MHC matched related donor) blood HCT. 17
patients with poor prognosis hematological malignancies re-
ceived cyclophosphamide (1gm/m2 days -7 and -6) and ﬂudara-
bine (25mg/m2 days -7 through -3) with sirolimus and tacroli-
mus, (both adjusted to 5-15ng/ml) and methotrexate (5mg/m2
days 1,3, 6) immunoprophyllaxis. Tacrolimus was tapered be-
tween days 40-100 in patients without acute GVHD. ATG
30mg/M was also given days -1,1,3, and 5. Median age was 61.
10 patients had acute leukemias, 6 had Non-hodgkins lym-
phoma and one Hodgkins disease. Only 6 patients were in
remission (CR) at the time of transplant, all of the other 11
having multiply pretreated active malignancy at HCT. Donor
cells engrafted stably in all patients (table below). 16/17
achieved 70% donor chimerism by day 30 and 11/13 90% by
day 100. 15/17 patients developed acute (d100) GVHD, but
this was grade 2 in only 4/17. In 1 patient GVHD developed
at day 121 only after discontinuation of both tacrolimus and
sirolimus. To date 2 patients remain alive free of any progres-
sion of malignancy 1216 and 1543 days post HCT. Only one of
these survivors was in CR at HCT, and this individual is now
enjoying a second remission more than 3 years longer than his
ﬁrst. 6 deaths have resulted from GVHD/Infection, while pro-
gressive malignancy (PD) has been the cause of mortality in 8
patients. One patient died of an unrelated cerebrovascular ac-
cident while free of disease or GVHD at 689 days from trans-
plant. We conclude that, while GVHD and transplant related
mortality remain obstacles, sirolimus and non-ablative condi-
tioning allow reliable engraftment of haplodentical donor HCT
with some long term survivors. These ﬁndings were in elderly
and inﬁrm patients with advanced hematological malignancy.
Engraftment of Haploidentical Cells*
D0 D15 D30 D60 D100
Mean Chimerism 0 0.73 0.88 0.94 0.98
Standard Deviation 0 0.38 0.19 0.15 0.05
Whole Blood Chimerism*
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A CRITICAL ROLE OF CD100 IN ALLOGENEIC IMMUNE RESPONSES
Duran-Struuck, R.1,2, Lowler, K.1, Beth, W.1, Luker, G.3, Liu, C.4,
Kumanogoh, A.5, Reddy, P.1, Ferrara, J.L.M.1 1University of Michigan
Cancer Center, Ann Arbor, MI; 2University of Michigan Unit for
Laboratory Animal Medicine, Ann Arbor, MI; 3University of Michigan
Dept of Microbiology & Immunology, Ann Arbor, MI; 4University of
Florida College of Medicine, Gainesville, FL; 5Osaka University, Osaka,
Japan.
Sema4D (CD100) is a novel 150 kDa protein that belongs to
the semaphorin family and has recently been shown to modulate
autoimmunity. We tested the requirement of CD100 expression
on T cells in regulating allo-immune responses. When alloge-
neic BALB/c stimulators were cultured with responder cells
from either wild type(wt) B6 or CD100 deﬁcient-/-B6, T cells
from the CD100-/-animals showed a ten fold less expansion
than the WT controls(10,800 /- 1,230 vs. 1,600 /- 258 cpm
p0.01). Consistent with the reduced proliferation, CD100-/-
T cells produced less IFN (1890 pg/mL) compared to B6 wt
Tcells (3478pg/mL) (p0.01). Similar reduction in prolifera-
tion and IFN  production was observed using anti-CD100
mAb’s (data not shown). We next determined the in vivo rele-
vance of CD100 expression on T cell allogeneic responses in a
well characterized experimental model of GVHD. We utilized
the B6(H2b) --BALB/c (H2 d) model where the donor and
recipient are mismatched at both major and minor histocom-
patibility antigens. Recipient BALB/c animals were irradiated
with 8Gy and transplanted with 5.0106 million bone marrow
(BM) cells from wtB6 animals together with 0.5 million T cells
from either wtB6 or CD100 -/- donors. Allogeneic recipients
that were injected with CD100 -/- donor Tcells showed signif-
icantly reduced mortality, less clinical and GVHD speciﬁc tar-
get organ damage (see table). Similar beneﬁt in the reduction of
GVHD was observed with anti-CD100 mAb treatment into the
recipients. When BALB/c recipient mice were challenged with
the P815 (H2 d) murine mastocytoma cell line and received wt
or CD100-/- B6 T cells, there was a signiﬁcant improvement in
the tumor free survival when compared to syngeneic recipients
thus demonstrating preservation of graft-versus-leukemia (90%
survival in allogeneic vs. 0% survival in syngeneic on day 12
post BMT p0.05). We next tested the hypothesis that absence
of CD100 expression on Tcells reduced the function of alloge-
neic APCs. When BALB/c DCs were treated with LPS and
co-cultured with CD100-/- B6 T cells, they secreted less
amounts of TNFa and IL12p70 compared to co-culture with wt
B6 Tcells (table). Use of antiCD100 mAb’s showed similar
results. In conclusion, we demonstrate a novel role for CD100
in regulating in vitro and in vivo allogeneic responses using these
two complementary approaches.
CD100-/- vs Wild Type Tcell in Vitro and in Vivo Outcomes
wt T cells
CD100-/- T
cells p value
OUTCOMES
GvHD Clinical Score
(day  60) 4.6/-0.8 1.8/-0.2 <0.02
Survival (day  60) 55% 100% <0.05
Liver Pathology (day
 60) 17.0/-1.5 9.0/-1.3 <0.01
Skin Pathology (day
 60) 1.5/-0.2 0.8/-0.2 0.02
Intestinal Pathology
(day  60) 7.8/-0.8 4.8/-1.0 0.03
CYTOKINES (pg/
mL)
IFNg serum d14
post BMT 584/-148 286/-97 <0.06
IFNg in vitro 3477/-254 1889/-221 <0.01
DC IL-12p70 in vitro 107/-7 68.5/-2 <0.01
DC TNFa in vitro 5930/-123 4252/-233 <0.01
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CD34 DOSE AND CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
AFFECT SURVIVAL IN ALLOGENEIC PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION (ALLOPBSCT) FOLLOWING NON-MYELOABLATIVE
(NM) CONDITIONING: THE VANDERBILT UNIVERSITY/NASHVILLE VA
SCT PROGRAM EXPERIENCE
Ewing, G.1,2, Giglia, J.1,2, Vusirikala, M.2, Ye, F.1, Shyr, Y.1,
Chinratanalab, W.1,2, Ruffner, K.1,2, Kassim, A.1, Jagasia, M.1,
Engelhardt, B.1, Brandt, S.1,2, Morgan, D.1,2, Stein, R.1, John, G.1,
Schuening, F.1, Goodman, S.1,2 1Vanderbilt University Medical Center,
Nashville, TN; 2Nashville Veterans Administration/Tennessee Valley
Healthcare System, Nashville, TN.
AlloPBSCT utilizing NM conditioning is hypothesized to
minimize the toxicity of myeloablative regimens while harness-
ing a potent graft vs malignancy effect. We sought to identify
factors predicting survival in a retrospective analysis of 60 pa-
tients (pts) undergoing alloPBSCT from HLA-matched related
donors between 8/00 and 8/05 at our program. All pts received
90 mg/m2 ﬂudarabine and 200 cGy TBI. GVHD prophylaxis
consisted of CSA/MMF. The median age was 55 years (range
41-66). Male: female was 51:9. All transplants were performed
for hematologic malignancies. The median number of treat-
ments prior to transplant was 4 (range 0-8). The mean cell doses
infused were 8.0 (range 3.5-16.3) x 106 CD34/kg and 28.4
(range 0.9-65.9) x 107 CD3/kg. Among 33 (55%) pts who
became neutropenic, the median time to ANC  500 was 21
days (range 14-49). Primary graft failure occurred in 2 patients.
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Of evaluable pts with chimerism data, median time to 100%
donor chimerism was day 28 for CD33 and day 180 for
CD3. AGVHD occurred in 42/60 (70%) pts (grade I in 14 and
grades II-IV in 28), and cGVHD occurred in 28/52 (54%); 12
pts developed extensive cGVHD. 14 pts required donor lym-
phocyte infusion for disease progression. 100-day NRM was
10% (all from aGVHD); another 2 patients died of disease
progression. After day 100, most pts died from disease pro-
gression or infection related to cGVHD. Kaplan-Meier proba-
bilities for overall survival (OS) and progression free survival
(PFS) at one year were 61% and 48%, respectively with median
follow up of 505 days (range 31-2029). OS at 2 and 3 years was
45% and 36%. In univariate analysis, the development of
cGVHD signiﬁcantly correlated with improved OS (p  0.02)
and PFS (p  0.01). Although CD34 and CD3 doses showed
no signiﬁcant association with development of cGVHD, higher
doses of both were associated with development of aGVHD (p
 0.01 and 0.04 respectively) and higher CD34 doses (6.8 vs
9.4106/kg) were associated with development of higher grades
of aGVHD (grades II-IV versus grades 0-I) (p  0.01). Incre-
mental increases in CD34 dose were associated with an in-
creased hazard ratio for death; however, a dose above 8 106
CD34/kg was associated with lower probability of relapse (p 
0.04). NM conditioning has a role in alloPBSCT and further
investigation to optimize disease indications and CD34 dosing
is needed.
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RAPAMYCIN GENERATED DONOR TH2/TC2 CELLS PREVENT GRAFT
REJECTION BY INHIBITION OF ALLOREACTIVITY AND NOT BY DELE-
TION OF ALLOREACTIVE T CELLS
Mariotti, J.1, Foley, J.1, Wong, E.1, Borenstein, T.1, Han, S.1,
Hanson, J.1, Fowler, D.H.1 1National Cancer Institute/NIH, Bethesda,
MD.
Ex vivo rapamycin generates murine Th2 cells that potently
abrogate GVHD. We thus hypothesized that rapamycin would
generate Th2/Tc2 cells (Th2/Tc2.R cells) that prevent fully
MHC-disparate hematopoietic stem cell (HSC) rejection. To
test this hypothesis, we utilized a model of rejection involving
lethal host irradiation and quantitative host T cell addback [see
cohorts, Table]. Th2/Tc2.R cell recipients had consistent allo-
engraftment (99% donor, n9/10; rejection, n1/10); in con-
trast, control Th2/Tc2 recipients had graft rejection (n9/10)
or mixed chimerism (n1/10). Post-BMT host-vs-graft re-
sponses (HVGR) were quantiﬁed by the following method: (a)
spleen cell harvest and enumeration; (b) 24 h host (syngeneic) or
donor (allogeneic) dendritic cell stimulation; (c) cell-surface
ﬂow cytometry with anti-CD4, anti-CD8 and anti-host antibod-
ies; (d) Miltenyi IFN-gamma cytokine capture ﬂow cytometry;
and (d) calculation of absolute number of host anti-donor allo-
reactive CD4 and CD8 T cells per spleen. Graft rejection
controls had increased post-BMT allospeciﬁc CD4 and
CD8 T cells secreting IFN-g (cohort 3cohort 2; p .001).
Prevention of rejection by donor Th2/Tc2.R cells abrogated
this HVGR (cohort 5cohort 3; p .001); in contrast, donor
Th2/Tc2 cells only partially reduced HVGR (cohort 4cohort
3; p .05). Cohorts 6, 7, 8, and 9 demonstrated that rapamycin-
generated donor T cells prevention of HVGR was attributable
to both CD4 and CD8 subsets and occurred independent of
perforin or fasL molecules associated with clonal deletion
mechansims. To evaluate whether alloreactive host T cells were
clonally deleted, the fate of 2C TCR transgenic T cells utilized
as host T cell addback was evaluated [BALB/c(H-2d) into B6(H-
2b) model]. Administration of a low-dose of donor Th2/Tc2.R
cells relative to host 2C TCR transgenic cells (200:1 ratio)
resulted in actual massive expansion of alloreactive 2C cells
(cohort 13 cohort 11, p.0001), increased allospeciﬁc IFN-g
release from 2C cells, and a resultant decrease in donor chimer-
ism; in contrast, administration of high-dose Th2/Tc2.R cells
(1000:1 ratio) resulted in similar expansion of alloreactive 2C
cells, but nominal acquisition allospeciﬁc IFN-g secretion
(94.480  13.030; cohort 14 vs cohort 13, p.0005) and in-
creased donor chimerism (p.0001). Taken together, rapamy-
cin-generated Th2 or Tc2 cells prevent rejection by a mecha-
nism that reduces host allospeciﬁcity without allospeciﬁc clonal
deletion.
Th2/Tc2R Cells: Abrogation of T cell mediated HVGR without
Deletion of Host Alloreactive T cells
B6 into BALB/c (Inocula)
Absolute #
CD8IFN-g
alloreactive
host T
(x10^3/spleen)
% Donor
cells
Cohort
1 HSC - 87  1
2 Host T 18  3 -
3 HSCHost T Addback 2,600  260 46  3
4 HSCHost Tcontrol T2 980  265 75  4
5 HSCHost TT2.R 48  9 92  1
6 HSCHost TTh2.R (CD4) 284  87 92  1
7 HSCHost TTc2.R (CD8) 142  42 89  1
8 HSCHost TT2.R PFN KO 32  8 97  1
9 HSCHost TT2.R FASL KO 4  2 98  0.1
BALB/c into B6 (Inocula; 2C
TCR Host Add-back)
Absolute # of
2C TCR
Alloreactive
host T
(x10^3/spleen)
% Donor
cells
10 BM - 11  1
11 Host T 46  10 -
12 BMHost T 19  2 3  1
13 BM Host T T2.R 200:1 1,182  125 10  1
14 BM Host T T2.R 1000:1 959  68 77  2
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HYPERGLYCEMIA DURING NEUTROPENIA WAS ASSOCIATED WITH
POOR OUTCOME IN PATIENTS UNDERGOING ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT)
Fuji, S.1, Kim, S.-W.1, Mori, S.-I.1, Fukuda, T.1, Kamiya, S.2,
Yamasaki, S.1, Tanosaki, R.1, Tobinai, K.1, Takaue, Y.1 1Department of
Hematology and Stem Cell Transplantation National Cancer Center
Hospital, Tsukiji, Tokyo, Japan; 2Department of Nutrition National
Cancer Center Hospital, Tsukiji, Tokyo, Japan.
Background Recipients of allogeneic HSCT frequently require
support with parenteral nutrition and immunosuppressive drugs, in
expectation of an increased risk of infections associated with hy-
perglycemia, particularly in the neutropenic period. Previous re-
ports showed that hyperglycemia was associated with morbidity
and mortality in ICU (ref van den Verge et al. N Engl J Med. 2001
Nov 8;345(19): 1359-67). There was no previous study which
assessed the clinical impact of hyperglycemia in patients undergo-
ing myeloablative HSCT. Patients and Methods A cohort of 112
consecutive adult patients with hematological malignancies treated
between January 2002 and June 2006 was reviewed retrospectively,
and 21 patients were excluded due to graft failure, preexisting
infectious diseases or preexisting neutropenia. The remaining 91
patients (Age median 35.5, 18-57) were categorized according to
mean fasting blood glucose (BG) level in the neutropenic period: 1)
“normoglycemia” (BG110 mg/dl, n28), 2) “mild hyperglyce-
mia” (110BG150 mg/dl, n49) and 3) “moderate and severe
hyperglycemia” (150 mg/dlBG, n14). Conditioning regimens
included BU/CY (n45), CY/TBI (n43) and CA/CY/TBI (n3).
GVHD prophylaxis included cyclosporine- (n62) and tacroli-
mus-based regimens (n29). Stem cell sources included bone mar-
row (n46), peripheral blood (n41) and cord blood cells (n4).
The primary endpoint of this study was the occurrence of febrile
neutropenia (FN) and infection during neutropenia. The second-
ary endpoints were parameters for organ dysfunction, aGVHD,
overall survival (OS) and treatment-related mortality (TRM). Re-
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